Abstract: A hydraulic arrangement including a supply port (5), a working port arrangement (20), a valve arrangement (3, 8, 21) controlling a supply of hydraulic fluid from the supply port (5) to the working port arrangement (20), a command device (20) controlling the valve arrangement (3, 8, 21), and a sensor arrangement (19) sensing at least a working condition of the hydraulic arrangement is described. In such a hydraulic arrangement a simple way should be given to achieve a safety functionality. To this end the valve arrangement (3, 8, 21) includes flow limiting means (9) operatively coupled to the sensor arrangement (19), wherein the flow limiting means (9) limit the flow to the working port arrangement (20) depending on the at least one working condition of the hydraulic arrangement.

Abstract: A hydraulic arrangement (1) including a supply port (P), a return port (T), a working port arrangement (L, R), and a valve (2) controlling a supply of hydraulic fluid from the supply port (P) to the working port arrangement (L, R), wherein the valve (2) includes a housing (4) and a spool (3) movable in lengthwise direction in the housing (4) and forming together with the housing (4) at least one flow path the resistance of which depends on the position of the spool (3) in the housing (4), and the spool (3) is actuated by a hydraulic pilot pressure (21, 22) in a pressure chamber (7, 8). In such a hydraulic arrangement a safety functionality should be achieved in a simple way. To this end the housing (4) includes a pilot pressure relief port (20) connected to the return port (T) via a shut-off valve (10) and the spool (3) after a predetermined stroke (13, 14) opens a connection between the pressure chamber (7, 8) and the pilot pressure relief port (20).

Abstract: The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.

Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.

Abstract: Herein is reported a method for generating a recombinant mammalian cell expressing a heterologous polypeptide and a method for producing a heterologous polypeptide using said recombinant mammalian cell, wherein in the recombinant cell the expression of at least the endogenous gene MYC has been reduced. It has been found that the knockout of at least the endogenous gene MYC in mammalian cells, e.g. such as CHO cells, improves recombinant productivity by the cells.